Dataset from Phase III Multicenter, Randomized, Double-Blind Placebo-Controlled Outpatient Study of Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

The study is designed to investigate the acute treatment efficacy, safety, and tolerability
of atomoxetine on a once-daily dosing strategy (in the morning). It incorporates a 6-week
acute treatment period and a 2-week discontinuation phase. The assessments in this study
include a standard assessment of ADHD symptomatology using a Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition™, investigator-administered rating scale.